:Rosaramicin

{{Chembox

| ImageFile = Rosamicin.svg

| ImageSize = 200px

| IUPACName = {(1S,2R,3R,7R,8S,9S,10R,12R,14E,16S)-3-Ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-9-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyloxy]-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl}acetaldehyde

| SystematicName = [(1S,2R,3R,7R,8S,9S,10R,12R,14E,16S)-9-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-3-ethyl-7-hydroxy-2,8,12,16-tetramethyl-5,13-dioxo-4,17-dioxabicyclo[14.1.0]heptadec-14-en-10-yl]acetaldehyde

| OtherNames = Rosamicin; Juvenimicin A3

|Section1={{Chembox Identifiers

| CASNo = 35834-26-5

| CASNo_Ref = {{Cascite|changed|CAS}}

| PubChem = 6537204

| ChemSpiderID = 5020508

| ChEMBL = 8965

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEBI = 87084

| EC_number = 252-742-1

| KEGG = D05757

| UNII = E907BNQ7SH

| SMILES = O=CC[C@@H]2[C@H](O[C@@H]1O[C@@H](C[C@H](N(C)C)[C@H]1O)C)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](C)[C@@H]3O[C@]3(\C=C\C(=O)[C@H](C)C2)C

| InChI = 1/C31H51NO9/c1-9-25-20(5)29-31(6,41-29)12-10-23(34)17(2)14-21(11-13-33)28(19(4)24(35)16-26(36)39-25)40-30-27(37)22(32(7)8)15-18(3)38-30/h10,12-13,17-22,24-25,27-30,35,37H,9,11,14-16H2,1-8H3/b12-10+/t17-,18-,19+,20-,21+,22+,24-,25-,27-,28-,29+,30+,31+/m1/s1

| InChIKey = IUPCWCLVECYZRV-JZMZINANBR

| StdInChI = 1S/C31H51NO9/c1-9-25-20(5)29-31(6,41-29)12-10-23(34)17(2)14-21(11-13-33)28(19(4)24(35)16-26(36)39-25)40-30-27(37)22(32(7)8)15-18(3)38-30/h10,12-13,17-22,24-25,27-30,35,37H,9,11,14-16H2,1-8H3/b12-10+/t17-,18-,19+,20-,21+,22+,24-,25-,27-,28-,29+,30+,31+/m1/s1

| StdInChIKey = IUPCWCLVECYZRV-JZMZINANSA-N

}}

|Section2={{Chembox Properties

| C=31 | H=51 | N=1 | O=9

| Appearance =

| Density =

| MeltingPt =

| BoilingPt =

| Solubility =

}}

|Section3={{Chembox Hazards

| MainHazards =

| FlashPt =

| AutoignitionPt =

}}

}}

Rosaramicin (rosamicin) is an antibacterial substance that is chemically a lipid-soluble basic macrolide similar to erythromycin but with a better activity against Gram-negative bacteria.{{cn|date=March 2023}}

Experiments in dogs have shown that it is more concentrated in the prostate than erythromycin is, and thus may be better for treating infections of that organ.{{cite journal |vauthors=Baumueller A, Kjaer TB, Madsen PO |title=Prostatic tissue and secretion concentrations of rosamicin and erythromycin. Experimental studies in the dog |journal=Invest Urol |volume=15 |issue=2 |pages=158–60 |date=September 1977 |pmid=903212 }}